Gilead's lenacapavir injection, shown in a rollout of its approved HIV treatment form called Sunlenca, is up for a PrEP approval decision on June 19 (Credit: Gilead)

June 13, 2025 10:30 AM EDT

In Focus

With HIV prevention under attack, how might Gilead’s new PrEP injection fare?

Kyle LaHucik

Biotech Correspondent

A groundbreaking new therapy that can almost entirely prevent HIV is days away from an FDA decision — but a mix of recent federal politics and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

With HIV prevention under attack, how might Gilead’s new PrEP injection fare?

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

Another round of consolidation is coming, FDA commissioner tells staff

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

FDA's oncology adcomm to review GSK's Blenrep relaunch plans

McKesson leads the charge in revolutionizing precision oncology in community practices

With HIV pre­ven­tion un­der at­tack, how might Gilead’s new PrEP in­jec­tion fare?

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

With HIV prevention under attack, how might Gilead’s new PrEP injection fare?

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

Another round of consolidation is coming, FDA commissioner tells staff

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

FDA's oncology adcomm to review GSK's Blenrep relaunch plans

McKesson leads the charge in revolutionizing precision oncology in community practices